Indonesian J. Pharm. Vol. 28 No. 2: 125 - 130

ISSN-p: 2338-9427

DOI: 10.14499/indonesianjpharm28iss2pp125

### **Research Article**

### THE EFFECT OF MEDICATION REMINDER CHART ON LEVEL OF ADHERENCE IN DIABETES MELLITUS TYPE 2 PATIENTS AT **RSUD SLEMAN YOGYAKARTA**

Yunita Suffiana, Fita Rahmawati\*, Tri Murti Andayani

Laboratory Pharmacology and Clinical Pharmacy, Faculty of Pharmacy. Universitas Gadjah Mada. Skip Utara 55281 Yogyakarta

**Submitted:** 12-08-2016 **Revised:** 25-09-2016 **Accepted:** 10-01-2017

\*Corresponding author Fita Rahmawati

malihahanun@yahoo.com

#### **ABSTRACT**

Patient adherence is a key factor that determines the outcome of diabetes mellitus therapy. This study was conducted to determine the effect of a medication reminder chart on level adherence and clinical outcome in patients with Type 2 diabetes mellitus. The experimental study used pretest-posttest design with control group was conducted during February until April of 2016 at Sleman Hospital in Yogyakarta. Patients were categorized into two groups of different subjects, who received of medication reminder chart tools were 40 patients (Code A) and the other 40 patients were assigned to control group (Code B). Morisky Medication Adherence Scale of 8-item (MMAS-8) was used to measure adherence. Clinical outcome were measured based on FBG decrease (mg/dl). Two independent sample t-test was using to determine the mean differences of the average score of the adherence level before and after using the medication reminder chart. The results of this study showed that Medication Reminder Chart compared control groups improved adherence (p=0.000) but did not improve clinical outcome (p=0.411). The pharmacist might use The Medication Reminder Chart to improve medication adherence for chronic disease.

**Key words:** Compliance, Clinical outcome, MMAS-8, Medication Reminder Chart

### INTRODUCTION

Diabetes mellitus was in the list of top 10 highest prevalence disease in Sleman (Dinkes Sleman, 2013). The type 2 of diabetes mellitus is one of metabolic disease with increasing prevalence over years, which one cause lower limb amputations, blindness, and kidney failure in 20-74 years old (CDC, 2009). The type 2 diabetes mellitus was chronic metabolic disease with multiple etiology characterized by hyperglycemia and impaired metabolism of carbohydrates, lipids and proteins as a result of insufficiency of insulin function. Insufficiency of insulin function is known to be caused by impaired or deficient production of insulin with beta Langerhans of the pancreas gland, or due to reduced the responsiveness of cells on insulin (Wells et al., 2009).

Patients who are non adherence to treatment could make serious problem and are great challenge in making a treatment succeed. The success of treatment is not only adherence,

but included also monitoring of blood glucose, dietary changes, care of foot hygene, and exercise (Santosa, 2011). Inadherence is suspected to be caused by factors related to the patient such as age, gender, education or related therapy patient as long diagnostics, complexity of treatment and side effects of drugs (Divya and Nadig, 2015). Based on the WHO report of 2003, the average long-term treatment of adherence in chronic diseases in developed countries reached 50%, while in developing countries is lower (Cramer, 2004). The study in Sudan, showed that medications adherence was 100 (44.2%) for patients on oral medications and 57 (45.6%) for insulin users (El-Hadiyah et al., 2016). The success of treatment in type 2 diabetes mellitus was influenced by patient adherence in taking medicine (BPOM, 2006)

One of the instruments used to assess the adherence patients with type 2 diabetes mellitus is the Morisky Medication Adherence Scale (MMAS-8) with eight item questionnaire developed by Morisky et al., (2008). This questionnaire has been evaluated with high reliability (0.83), high sensitivity and specificity (Morisky *et al.*, 2008). Another method for assessing adherence was pill count. Pill count was known to have high accuracy (Lam and Paula, 2015).

In this study, Medication Reminder Chart tools used to improve patient adherence with medication use. This method was chosen because it offers cheap, easy method that had proven its capability to improve adherence with medication use (Conn et al., 2009).

# MATERIAL AND METHODS Subjects research

Subjects were outpatients with type 2 diabetes mellitus with complication such are hypertension, dislipidemia, neuropathy diabetic, and chronic heart failure. The study begin in February until March of 2016 at Sleman Hospital in Yogyakarta. The total number of patients is 80. The number of subjects was obtained from sample size calculation in experimental studies, where the outcome varians ( $\sigma^2$ ) is 47,82 and  $\mu_1$  . $\mu_2$  are 158,0 – 126,9 that were obtained from research conducted by Wishah et al., (2015) and the results obtained from sample size calculation in this study is 29 patients, typically added 20% to avoid drop out (29 + 6 = 35 patients), so in this study required minimal of 35 subjects of each groups. The subjects were divided into two groups. The first group was given the intervention of Medication Reminder Chart which consisted of 40 patients and control group consisted of 40 patients. Inclusion criteria were patients who was diagnosed with type 2 diabetes mellitus or with complication, subjects ≥ 26 years old, fasting blood glucose ≥ 100 mg / dl, patients adherence with scale of MMAS less than 8, patients who never used Medication Reminder Chart before, willing to participate in the study by signing an informed consent. Exclusion criteria were pregnant patients.

The Medication Reminder Chart is a tool or medical records used by patients after taking medication. The part of medication reminder consists of drugs name, indication, and the strength of doses were designed by researchers with reference to the meta-analysis which is conducted by Conn *et al.*, (2009). Medication reminder chart is benefecial for patients who

have gotten complex treatment, as well as useful for patients who use one or two of drug with specific problems when the patients has activity outside or difficulty to remember taking medication at a certain time (Raynor, 2011).

#### Research data

Data obtained from medical records included age, gender, education employment history, body mass index, long term diagnose, smoking history, comorbid, diet of carbohydrate, type of treatment, physical fasting blood glucose level and interviewed with patients included using of Medication Adherence Morisky Scale Questionnaire with eight items questionnaire Data were obtained pill count. prospectively and sampling methods using random allocation sampling determined with random numbers (0-99) with 6 bloks sequences patterns A and B, A code assiegned for Medication Reminder Chart and B for Control groups, randomization was done using Microsoft Excel.

Adherence of patients was evaluated by MMAS-8 questionnaire cales that categorize patients into three categories of adherence. The first one was high adherence patients with a score of 8 on the scale, medium adherence with a score of 6-7, and low adherence with a score < 6 (Morisky *et al.*, 2008). Therapy outcome of fasting blood glucose level measuring before and after intervention. Expected therapy goal of fasting blood glucose is < 110mg/dL.

### **Analysis of research finding**

Patients was classified by age, gender, education and employment history, type of treatment, body mass index, long term diagnose, smoking history, comorbid, diet of carbohydrate, physical exercise were analyzed with Chi-Square statistic to investigate whether distributions of categorical variables differ from one another. The adherence with MMAS-8 questionnaire and clinical outcome were determined before and after treatment. Kolmogorov smirnov test is used to evaluate the variable data is sufficiently normal. The adherence scale (MMAS-8) questionnaire and clinical outcome (FBG) (mg/dl).

PP 1 1	-	01		•					•	•	•	
Labla		I havactor	actic.	dota		mod	cotion	romindor	chart	and	control	OPPOSITOR
Ladic	Ι.	Character	ISLIC	S CIALZ	1. () [	HICG	ICALIOIT	reminder	CHAIL	and	COHEO	210005

Characteristics		Medication Reminder Chart n (%)	Control n (%)	Total Subject n (%)	p value	
Gender	Male	13 (32.5)	14(35)	27(33.75)	$0.813^{a}$	
Gender	Female	27 (67.5)	26(65)	53(66.25)	0.813ª	
<b>A</b> ~~	Adult	28(70)	19 (47.5)	47(58.75)	0.041a	
Age	Elderly	12 (30)	21 (52.5)	33(41.25)	0.041"	
	Underweight	2 (5)	1 (2.5)	3 (3.75)		
Body weigh	nt Normal weight	18 (45)	19 (47.5)	37 (46.25)	$0.747^{a}$	
, ,	Overweight	20 (50)	20 (50)	40 (50)		
	Uneducated	1(2,5)	1(2.5)	2(2.5)		
Education	Elementary	13(32,5)	16 (40)	29(36.25)	$0.508^{a}$	
	High School	26 (65)	23 (57.5)	49 (61.25)		

Table II. Characteristics data of medication reminder chart and control groups

Characteristics		Medication Reminder	Control	Total Subject	p	
Characte	iistics	<i>Chart</i> n (%)	n (%)	n (%)	value	
Occupation	Occupied	18 (45)	14 (35)	32 (40)	0.361a	
Occupation	Not occupied	cupied 22 (55) 26 (		48 (60)	0.501	
Carbohydrate	Controlled	23 (57.5)	25 (62.5)	48 (60)	$0.648^{a}$	
Diet	Uncontrolled	17 (42.5)	15 (37.5)	32(40)		
Physical exercise	Regular	3 (7.5)	1 (2.5)	4(5)	$0.308^{a}$	
Filysical exercise	Not regular	37 (92.5)	39 (97.5)	76 (95)	$0.30\delta^a$	
Smoking	Yes 4 (10)	4 (10)	7 (17.5)	11(13.75)	0.330a	
Sillokilig	No	36 (90)	33 (82.5)	69(86.25)	0.330"	
Diagnosed for	< 1 year	3(7.5)	7(17.5)	10 (12.5)		
DM	1-5 years	11(27.5)	11(27.5)	22(27.5)	$0.369^{a}$	
DM	< 5 years	26(65)	22(55)	48(60)		
	DM	10(25)	7 (17.5)	17(21.25)		
Comorbid	DM + HT	21(52.5)	16 (40)	37 (46.25)	$0.160^{a}$	
	DM + others	9 (22.5)	17 (42.5)	26(32.5)		
Prescription of	Single	15(37.5)	15 (37.5)	30(37.5)	1.0a	
antidiabetic	Combined	25 (62.5)	25(62.5)	50(62.5)	1.U <sup>a</sup>	

Data pairs which were not normally distributed were analyzed with Two Independent samples t-test (Wilcoxon), while paired data which were normally distributed were analyzed with Two Independent samples t-test (Mann-Whitney).

## **RESULTS AND DISCUSSIONS Patient characteristics**

Characteristics of subjects in this study was analyzed to determine the proportions between the treatment group and control in baseline conditions (Table I).

The results from whole characteristics data analysis upon the two study groups

insignificant value of p>0.05, with similar proportion between the two groups. Characteristic data of the subjects age showed significant value of p<0.05, which showed different proportion between two groups.

## Identification of adherence with pill count after treatment

Table II showed that pill count analysis result was categorized into two groups. The first group for adherent patients with score of 80-100% and non-adherent patients with score under 80%.

Table III. Profile of patient adherence with pill count

Dationto adharana mafila	Medication H	Control		
Patients adherence profile	N	0/0	N	%
Adherent	21	52.5	15	37.5
Non adherent	19	47.5	25	62.5

Table IV. The median difference of adherence effect measured with MMAS-8 score of medication reminder chart and control groups.

Grouping	Median (Maximum-Minimum)	p value	Median different
Medication Reminder Chart	1.50 (3-0)	$0.000^{a}$	0.5
Control	1.00 (3-0)		

Profile of patient adherence by pill count of Medication Reminder Chart group was higher with percentage of 52.5%, compared to control groups with percentage of 47.5% (Table III).

### The effect of medication reminder chart to patient adherence

Blood glucose control was significantly associated with adherence to treatment thus reducing the complications of diabetes, hospitalizations, costs, and mortality. Medication Reminder Chart was effective in improving patient adherence with risk of therapy regiments complexity (Manmohan et al., 2012). The Median difference of adherence measured with MMAS-8 score of Medication Reminder Chart and control group, in this study using a non-parametric analysis with Two Independent Samples test (Mann-Whitney) for data unpaired groups (Table IV).

A significant effect of Medication Reminder Chart to increase adherence of MMAS-8 score from pre-test to post-test higher than control group with p value p=0.000 and median different of 0.5. This study same as the research conducted by Conn *et al* which shown that intervention of Medication Reminder Chart could improve adherence, especially in elderly patients in treatment (Conn *et al.*, 2009) (Table IV) .

### The effect of medication reminder chart on clinical outcome

One of the key factors to achieve therapeutic goals is patient adherence. Low

adherence could affect bad clinical outcome. Optimal adherence of tretament would successfully improve therapeutic efficacy in the treatment of all chronic diseases and improved quality of life patients (Santosa, 2011). The Median different of clinical outcome in Medication Reminder Chart and control group (Table IV).

The result form table IV showed insignificant effect of Medication Reminder Chart compared to control groups in the decrease of fasting blood glucose level in type 2 diabetes mellitus patients with p value p=0.411 and median difference of 5.5. Basically the improvement of clinical outcomes affected by increased adherence, which in this study was measured based interviews with on questionnaires MMAS-8. The results showed patients adherence was increased after giving medication reminder chart, but even with increased adherence, the number of forgetting patients greater in adult category which was caused by being busy on working that sometimes lead them to be forgotten to take medication. Other than that, based on the results of interviews, some patients forgot to fill medication Reminder Chart after taking medication because of being busy, while others were not filling the medication Reminder Chart because they assumed that they know the schedule for taking the medication (thinks that filling the chart was not important), and others consider medication Reminder Chart is needed to help them remember the schedule for taking the medication and could be disciplined in

Table V. Median different of FBG in Medication Reminder Chart and control Group

Groups	Median (Maximum-Minimum) (mg/dL)	p value	Median different
Medication Reminder Chart Control	16 (200-(-73) <b>10.50 (295-(-132)</b>	0.411a	5.5

Table VI. Spearman Correlation Analysis between adherence and clinical outcomes of patients with Type 2 diabetes mellitus

Variable	p value	R
MMAS- FBG (mg/dL)	0.029	0.213

taking medicine. Therefore it is considered important to inform patients to use medication Reminder Chart to improve adherence. The results of the analysis showed the correlation between adherence and clinical outcomes in patients with Type 2 diabetes (Table V).

Correlation between adherence and FBG levels with a significance p=0.029, and positive correlation coefficient of (r=0.213), it means that higher adherence would increase the clinical outcome, the strength of the correlation is weak (r=0.2- < 0.4), which indicated while the correlation was positive, but compared to the clinical outcome between the two groups, it could not significantly decrease fasting blood glucose level after Medication Reminder Chart (Table VI).

The success of treatment was not completely influenced by adherence of drug use. The success of therapy in type 2 diabetes mellitus could be improved by controlling the diet, monitor blood glucose levels and exercise (Santosa, 2011).

### **CONCLUSION**

Medication Reminder Chart could improve adherence of patients compared to control group in Type 2 diabetes mellitus patients (p = 0.000) with median difference of 0.5. Medication Reminder Chart could not improve clinical outcomes in treatment group compared to control groups in patients with Type 2 diabetes mellitus (p = 0.411) with median difference of 5.5. Increased compliance could increased clinical outcome (p = 0.029),

with a positive correlation and the strength of weak correlation (r = 0.213).

### LIMITED STUDY AND SUGGESTION

Many factors can not be controlled in type 2 diabetes mellitus outpatient such as diet, excercise etc. Required modifications Medication Reminder Chart more informative (name of medication, dosage, frequency of use, indications, schedule for taking medication) and the instructions for filling the sheet of Medication Reminder Chart.

#### **REFERENCES**

BPOM, 2006. Kepatuhan Pasien: Faktor Penting Dalam Keberhasilan Terapi. Badan POM Republik Indonesia, Jakarta.

Cramer JA., 2004. A Systematic Review of Adherence With Medications for Diabetes. *Diabetes Care*, **27**: 1218–1224.

CDC, 2009. The Power of Prevention Chronic disease the public health challenge of the 21st century.

Divya, S. dan Nadig, P., 2015. Factors
Contributing To Non-Adherence To
Medication among Type 2 Diabetes
Mellitus In Patients Attending Tertiary
Care Hospital In South India. *Asian J. Pharm. Clin. Res.*, 8: 2

El-Hadiyah TM., Abdelhaleem MM., Hisham MA., Abubakr K., 2016. Factors Affecting Medication Non Adherence in Type 2 Sudanese Diabetic Patients: Pharmacology & Pharmacy, 7,141-146.

Lam WY., Paula F., Medication Adherence Measures: An Overview, *BioMed Research* 

- International Volume 2015, Article ID 217047, 12 pages http://dx.doi.org/10.1155/2015/217047
- Morisky DE., Ang A., Krousel-Wood M., Ward HJ., 2008. Predictive Validity of A Medication Adherence Measure in an Outpatient Setting. J. Clinical hypertension (Greenwich, Conn.), 10: 348–354
- Conn VS., Hafdahl AR., Cooper PS., Ruppar TM., Mehr DR., Russell CL., 2009. Interventions to improve medication adherence among older adults: metanalysis of adherence outcomes among randomized controlled trials. *The Gerontologist*, **49**: 447–462.
- Dinas Kesehatan Kabupaten Sleman, 2013, *Profil Kesehatan Sleman 2013* Sub Bagian Perencanaan dan Evaluasi, Sleman.
- Raynor T. 2011. Medication Reminder Chart- a Key Tool For Delivering The New

- Medicine Service. *The Pharmaceutical Journal*. September 2011.
- Santosa M., 2011, Pengenalan Penyakit DM Dan Penanganannya Dewasa ini, http://www.pbpapdi.org/papdi.phppb= detil\_berita&kd\_berita=87(diakses tanggal 25 januari 2016)
- Wells BG., Dipiro JT., Schwinghammmer TL., Dipiro CV., 2009. *Pharmacotherapy Handbook*.McGraw-Hill Medical Pub.Division, New York.
- Wishah RA., Omar AA., Abla MA. 2015.

  Impact of Pharmaceutical Care
  Intervention on Glycemic Control and
  Other Health-Related Clinical Outcome
  in Patients with Type 2 Diabetes:RCT,
  Diabetes and Metabolic Syndrome:
  Clinical Research & Reviewes 9 271-276.